China and COVID-19 offer test case for blockchain

5 May 2020

The COVID-19 pandemic did not stop China from launching its national blockchain-based service network (BSN) last month.

In fact, the launch of the service, which represents an attempt to promote the mass adoption of blockchain and explore the opportunities that the digital economy can bring, might well be particularly timely.

"Can we trust authorities with information without having a clear visibility on what they are doing with it?"According to GlobalData, China has been an early adopter of technologies to fight COVID-19 and will be closely observed by other countries on how to leverage technologies such as blockchain to contain and monitor the virus or any future outbreaks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK